A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting
NCT ID: NCT01926912
Last Updated: 2015-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
371 participants
OBSERVATIONAL
2013-05-31
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate
NCT02532842
An Efficacy and Safety Study of Paliperidone Palmitate in Participants With Schizophrenia
NCT01299389
A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia
NCT01527305
A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics
NCT01685931
Paliperidone Palmitate Flexible Dosing in Schizophrenia
NCT01281527
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants with schizophrenia
No intervention
This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant admitted to hospital due to an exacerbation of their schizophrenia prior to any study-related activity
* Participant may, in the opinion of the participating physician, benefit from treatment with paliperidone palmitate which will be initiated within 3 weeks after admission to hospital
Exclusion Criteria
* Participant has previously been treated with paliperidone palmitate
* Participant has a history of neuroleptic malignant syndrome
* Participant was on clozapine or has previously been treated with any long-acting injectable antipsychotic during the last 3 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen-Cilag International NV
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen-Cilag International NV Clinical Trial
Role: STUDY_DIRECTOR
Janssen-Cilag International NV
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Diest, , Belgium
Saint-Servais, , Belgium
Tournai, , Belgium
Pazardzhik, , Bulgaria
Rousse, , Bulgaria
Sofia, , Bulgaria
Stara Zagora, , Bulgaria
Targovishte, , Bulgaria
Vratsa, , Bulgaria
Elsinore, , Denmark
København S, , Denmark
Berlin, , Germany
Chemnitz, , Germany
Dresden, , Germany
Greifswald, , Germany
Hamburg, , Germany
Hennigsdorf, , Germany
Neuruppin, , Germany
Pfaffenhofen, , Germany
Sachsen, , Germany
Heraklion Crete, , Greece
Ioannina, , Greece
Katerini Pieria, , Greece
Thessaloniki, , Greece
Bat Yam, , Israel
Tel Litwinsky, , Israel
Almaty, , Kazakhstan
Astana, , Kazakhstan
Kyzylorda, , Kazakhstan
Taraz, , Kazakhstan
Ust-Kamenogorsk, , Kazakhstan
Chelyabinsk, , Russia
Moscow, , Russia
Nizhny Novgorod, , Russia
Omsk, , Russia
Orenburg, Staritsa Village, , Russia
Saint Petersburg, , Russia
Tula Region, , Russia
Yaroslavl, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
HOSPItal Use of Paliperidone Palmitate - A Prospective Non-Interventional Study
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R092670SCH4017
Identifier Type: OTHER
Identifier Source: secondary_id
CR100862
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.